LabyRx Immuno-Oncology
LabyRx is a clinical-stage immuno-oncology company focused on developing next-generation therapeutic vaccines and antibody therapies to improve cancer treatment worldwide. Their flagship product, LabVax, is a synthetic peptide vaccine targeting adenocarcinomas, designed to harness the immune system to fight cancer with high precision and minimal side effects. The company is dedicated to advancing cancer immunotherapy through innovative platforms, clinical trials, and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
LabyRx Immuno-Oncology
Products
Labyrinthin-derived synthetic peptide cancer vaccine (clinical-stage)
A clinical-stage synthetic peptide vaccine platform derived from a tumor-associated antigen designed to induce both antibody and T‑cell responses against adenocarcinoma tumors; developed for use alone or in combination with adjuvants and checkpoint inhibitors.
Labyrinthin-derived synthetic peptide cancer vaccine (clinical-stage)
A clinical-stage synthetic peptide vaccine platform derived from a tumor-associated antigen designed to induce both antibody and T‑cell responses against adenocarcinoma tumors; developed for use alone or in combination with adjuvants and checkpoint inhibitors.
Services
Clinical development and trial collaboration
Collaborative planning and execution of early-stage oncology clinical trials with academic and national research centers, including regulatory coordination and patient enrollment strategies.
Biomarker assay development and diagnostic support
Development of assays to detect tumor-associated antigen expression for diagnostics, patient selection, and monitoring of therapeutic response.
Preclinical efficacy testing and translational studies
In vitro and in vivo testing services including cell culture assays and patient-derived xenograft studies to evaluate therapeutic candidates prior to clinical development.
Clinical development and trial collaboration
Collaborative planning and execution of early-stage oncology clinical trials with academic and national research centers, including regulatory coordination and patient enrollment strategies.
Biomarker assay development and diagnostic support
Development of assays to detect tumor-associated antigen expression for diagnostics, patient selection, and monitoring of therapeutic response.
Preclinical efficacy testing and translational studies
In vitro and in vivo testing services including cell culture assays and patient-derived xenograft studies to evaluate therapeutic candidates prior to clinical development.
Expertise Areas
- Therapeutic cancer vaccine development
- Monoclonal antibody therapeutics
- Biomarker discovery and diagnostic assay development
- Early-stage oncology clinical trials (Phase I/II)
Key Technologies
- Synthetic peptide vaccine constructs
- Monoclonal antibody generation
- Immunoassays for antigen detection (diagnostic assays)
- Patient-derived xenograft (PDX) models